20 results on '"Chopra, Supriya"'
Search Results
2. Patterns of First Relapse and Outcome in Patients with Locally Advanced Cervical Cancer After Radiochemotherapy: A Single Institutional Experience
- Author
-
Sasidharan, Ajay, Mahantshetty, Umesh M., Gurram, Lavanya, Chopra, Supriya, Engineer, Reena, Maheshwari, Amita, Gupta, Sudeep, Deodhar, Kedar, Rangarajan, Venkatesh, Thakur, Meenakshi, and Shrivastava, Shyam Kishore
- Published
- 2019
- Full Text
- View/download PDF
3. Co-occurrence of symptoms after radiochemotherapy in locally advanced cervix cancer patients: a cluster analysis.
- Author
-
Pelizzola, Marta, Tanderup, Kari, Chopra, Supriya, Jürgenliemk-Schulz, Ina M., Nout, Remi, Kirchheiner, Kathrin, and Spampinato, Sofia
- Subjects
NAUSEA -- Risk factors ,CANCER patient psychology ,RESEARCH ,VAGINAL diseases ,SCIENTIFIC observation ,PAIN ,URINARY tract infections ,HEALTH outcome assessment ,PHYSICIANS' attitudes ,REGRESSION analysis ,GASTROINTESTINAL diseases ,CHEMORADIOTHERAPY ,CANCER patients ,FACTOR analysis ,QUALITY of life ,RESEARCH funding ,CERVIX uteri tumors ,CLUSTER analysis (Statistics) ,FATIGUE (Physiology) ,INSOMNIA ,HOT flashes ,COMORBIDITY ,LONGITUDINAL method ,DISEASE risk factors ,SYMPTOMS - Abstract
State of the art combined radiochemotherapy and image-guided brachytherapy for locally advanced cervical cancer (LACC) has shown improved disease control and survival as well as a significant reduction of organ related morbidity. However, LACC cancer survivors are still experiencing a spectrum of symptoms. The aim of this study was to identify co-occurring symptoms in cervix cancer survivors by using patient-reported outcome and physician assessed morbidity. EMBRACE I is a multicenter prospective observational study with 1416 LACC patients (2008–2015). Information on physician-assessed morbidity and patient-reported outcome was assessed at baseline and at regular follow-ups up with the CTCAE v.3 and EORTC-C30/CX24, respectively. Patients with at least 2 years of follow-up were included and data from 3 months to 2 years was used in the analysis. Factor analysis was used on both EORTC and CTCAE data with symptoms and follow-ups as observations. The extracted factors represent clusters of symptoms. Subsequently, regression models were built to investigate associations between the symptom clusters and QOL. The analysis included 742 patients. Despite the differences in the definition of physician-assessed and patient-reported symptoms, similar clusters are identified by the two assessment methods. Three main organ-related clusters are recognized for urinary, gastro-intestinal and vaginal morbidity. Furthermore, a general symptoms cluster where fatigue, pain, insomnia, neuropathy, and hot flashes have large weights is found. Lastly, a cluster with nausea, vomit and lack of appetite is also identified. The general, gastrointestinal and nausea clusters show significant associations with general QOL. This analysis on both PRO and physician-assessed morbidity found a cluster associated with general symptoms and organ-related symptom clusters (urinary, gastrointestinal, vaginal). This shows that LACC survivors experience a variety of co-occurring symptoms. Our analysis also shows that the cluster of general symptoms is associated with a decrease in QOL. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Positioning high-dose radiation in multidisciplinary management of unresectable cholangiocarcinomas: Review of current evidence
- Author
-
Chopra, Supriya, Mathew, Ashwathy S., Engineer, Reena, and Shrivastava, Shyam K.
- Published
- 2014
- Full Text
- View/download PDF
5. Serial Bone Density Changes in Women Undergoing Pelvic (Chemo) Radiation: Results From the PARCER Trial.
- Author
-
Chopade, Pradnya, Chopra, Supriya, Jain, Jeevanshu, Panda, Subhojit, Patil, Akshay, Patil, Gayatri, Mahantshetty, Umesh, Engineer, Reena, Gurram, Lavanya, Mittal, Prachi, Ghosh, Jaya, Gupta, Sudeep, and Shrivastava, Shyam Kishore
- Subjects
- *
BONE density , *BONE health , *LUMBAR vertebrae , *RADIOTHERAPY , *BONE densitometry , *CLINICAL trials , *PUBIC symphysis , *PELVIC bones - Abstract
Purpose: Pelvic irradiation leads to substantial dose to the pelvic girdle. However, bone density loss as a function of radiation therapy dose and time has not been investigated. This study was undertaken to evaluate such a dose-response relationship.Methods and Materials: Women undergoing pelvic radiation therapy for cervix cancer within a phase 3 trial were included. The study necessitated 2 computed tomography imaging sets acquired at least 12 months apart in patients with no evidence of relapse. All images were transferred to the treatment planning system to determine radiation dose and Hounsfield unit (HU). Across the entire lumbopelvic region (lumbar 1-5 [L1-5] vertebrae, pubic symphysis, femur, acetabulum, greater trochanter, and anterior-superior iliac spine) multiple regions were defined to measure radiation therapy dose and HU. Bone health was categorized as normal if >130 HU, osteopenic at 110 to 130 HU, and osteoporotic <110 HU at baseline and follow-up. Univariate analysis was performed to test the effect of various factors on HU. Further interaction among radiation therapy dose, time, and HU was assessed using a linear mixed model.Results: Overall, 132 of 300 patients were eligible. The median age was 49 (42-56) years. With a prescription dose of 50 Gy, the L1 and L2 vertebrae received a median dose of 1.2 and 4 Gy, respectively, and L3-5 received 10 to 50 Gy. At 24 months, median HU loss at L4-5 was 45 HU (interquartile range, 34-77 HU). Out of the 132 patients, at baseline 96% had normal bone health. However, at the last follow-up, 3% of patients had normal bone health, 12% developed osteopenia, and 85% developed osteoporosis (P < .001). There were no patient- or treatment-related factors predicted for HU loss on univariate analysis. HU loss >60 to 70 was observed at >45 Gy at L5 vertebra (60-70 HU, P < .02) and >15 Gy at L4 vertebra (33 HU; P = .04).Conclusions: Dose-response relationship is observed between radiation dose and bone mineral density loss. Prospective studies are needed to corroborate these observations and design future interventions. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
6. Patterns of Relapse After Adjuvant Chemoradiation for Cervical Cancer in a Phase 3 Clinical Trial (PARCER): An Evaluation of Updated NRG Oncology/RTOG Target Delineation Guidelines.
- Author
-
Mittal, Prachi, Chopra, Supriya, Charnalia, Mayuri, Dora, Tapas, Engineer, Reena, Mulani, Jaahid, Scaria, Libin, Prajapati, Kunal, Kannan, Sadhana, Gurram, Lavanya, Mahantshetty, Umesh, Gupta, Sudeep, and Shrivastava, Shyam Kishore
- Subjects
- *
CLINICAL trials , *CERVICAL cancer , *RADIOTHERAPY treatment planning , *CHEMORADIOTHERAPY , *RADIOTHERAPY , *ONCOLOGY , *ENDOMETRIAL cancer , *GYNECOLOGIC cancer , *COMPUTERS in medicine , *RESEARCH , *RESEARCH methodology , *CANCER relapse , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials ,CERVIX uteri tumors - Abstract
Purpose: The Radiation Therapy Oncology Group (RTOG) under NRG Oncology recently published updated contouring guidelines for intensity modulated radiation therapy in postoperative treatment for endometrial and cervical cancer. The present study was designed to evaluate the implications of newly published guidelines.Methods and Materials: We recruited 300 patients in a phase 3 randomized controlled trial of adjuvant chemoradiation therapy for cervical cancer (NCT01279135) to understand patterns of relapse. For those patients with pelvic relapse, we imported radiation therapy structure sets, treatment plans, and diagnostic images at relapse on the treatment planning system. We performed rigid registration with treatment planning images that contained the delineated planning target volume and radiation dose information. We delineated gross tumor volume at time of relapse on the diagnostic scans and superimposed it on the radiation therapy treatment scans. We categorized the site of pelvic relapse as "within field of old RTOG/[Postoperative Adjuvant Radiation in Cervical Cancer (PARCER)] target delineation guidelines" or "within field of new NRG/RTOG guidelines," or both, and compared proportions of recurrences contained within the 2 guidelines. We consider a P value of <.05 statistically significant. Additionally, we generated intensity modulated radiation therapy treatment plans based on the new guidelines for a limited set of patients to see if these new guidelines increased the organ at risk doses.Results: Most common form of relapse was distant metastasis (15%). Pelvic relapse rate in our study was 8%. Overall, 9 out of 19 relapses were encompassed in the contouring guidelines of the old RTOG/ Postoperative Adjuvant Radiation in Cervical Cancer (PARCER) trial, and 12 out of 19 were encompassed within the new RTOG 2021 contouring guidelines. This corresponded to a further 1% reduction in local relapses (P = .007). Dose to rectum was marginally increased with the new contouring, with no difference in other organs at risk. Salvage treatment was offered in 25 out of 60 patients who relapsed. Patients who received local treatment after relapse had a mean survival after relapse of 27.2 months compared with 8 months among those who received supportive care alone.Conclusions: Our study supports the use of newly published NRG/RTOG contouring guidelines in patients with cervical cancer who have undergone hysterectomy. Further data are needed to ascertain if anterior extension of the clinical target volume is needed as in the Postoperative Adjuvant Radiation in Cervical Cancer trial. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
7. Temporal course of late rectal toxicity & impact of intervention in patients undergoing radiation for cervical cancer.
- Author
-
Shejul, Jagadish, Chopra, Supriya, Ranjan, Nilesh, Mahantshetty, Umesh, Mehta, Shaesta, Patil, Prachi, Engineer, Reena, Gurram, Lavanya, Phurailatpam, Reena, Swamidas, Jamema, Gupta, Sudeep, and Shrivastava, Shyam
- Subjects
- *
CERVICAL cancer , *COST control , *CANCER patients , *DIRECT costing , *UNIVARIATE analysis - Abstract
Background & objectives: There is limited information available on the temporal course of late stage radiotherapy adverse effects. The present study reports on the temporal course of late toxicities after chemoradiation and brachytherapy. Methods: Women with cervical cancer who presented with late toxicity after (chemo) radiation were included in the study. Grade of toxicity (Clinical Toxicity Criteria for Adverse Events version 4.03) and type of intervention were recorded at three-monthly interval for the first year and then six monthly until 24 months. Direct cost for the management of toxicity was calculated. Univariate analysis was performed to understand the impact of various factors on persistence of toxicity. Results: Ninety two patients were included in this study. Grades I, II, III and IV toxicities were observed in 50 (54%), 33 (36%), 7 (8%) and 2 (2%) patients, respectively, at first reporting. Patients spent a median of 12 (3-27) months with toxicity. At 12 months, 48/92 (52.2%) patients had a complete resolution of toxicity, whereas 27/92 (29.3%) patients had low grade (I-II) persistent toxicity. Only 6/92 (6.5%) patients who had grade III−IV toxicity had resolution to a lower grade. Four (4.3%) patients died due to toxicity. At 24 months, 9 (10%) patients continued to have grade ≥ III toxicity. On an average, 7 (2-24) interventions were required for the clinical management of late toxicity and median direct cost incurred was ₹ 50,625 (1,125-303,750). Interpretation & conclusions: In this study late radiation toxicity resolved within 12 months in more than half of patients. However, others are likely to have had persistent lower grade toxicity or progression to higher grade. Structured strategies are hence needed for the effective management of late toxicities. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Defining the role of high-dose radiation in oligometastatic & oligorecurrent cervical cancer.
- Author
-
Mangaj, Akshay, Chopra, Supriya, and Nout, Remi A.
- Subjects
- *
CERVICAL cancer , *CANCER relapse , *SYMPTOMS , *RADIOTHERAPY , *DISEASE eradication - Abstract
Around 5-8 per cent of women diagnosed with cervical cancer present with metastatic disease at presentation and 16-25 per cent of patients fail at either within irradiated fields or at distant sites post-curative therapy in advanced cervical cancers. Conventionally, chemotherapy with palliative intent constituted the mainstay of treatment with modest survival outcomes and radiation therapy was reserved for symptomatic benefit only. While targeted therapies and immunotherapy have been added in therapeutic armamentarium, the impact on the outcomes is modest. In limited metastatic disease, radiation therapy to metastatic sites from different primary cancers has shown survival benefits; however, the data are scarce in cervical cancer. With a better understanding of the molecular biology of the metastases and recurrence pattern, emphasis is laid upon total eradication of the disease rather than offering relief from symptoms. This article summarizes the role of radiation therapy in limited metastatic disease and recurrent cervical cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Addition of short course radiotherapy in newly diagnosed locally advanced rectal cancers with distant metastasis.
- Author
-
Jain, Shanu, Engineer, Reena, Ostwal, Vikas, Ramaswamy, Anant, Chopra, Supriya, Desouza, Ashwin, Lewis, Shirley, Arya, Supreeta, Patil, Prachi, and Saklani, Avanish
- Subjects
METASTASIS ,RECTAL cancer ,TUMOR surgery ,RADIOTHERAPY ,CANCER radiotherapy ,HEMORRHAGE ,PREVENTIVE medicine - Abstract
Aim: To study the outcomes of patients presenting with locally advanced rectal cancers with distant metastasis (mLARC), treated with short course radiotherapy (SCRT). Method: Between May 2012 and August 2015, 70 patients diagnosed with mLARC, treated with SCRT (25 Gy/5#) and three to six cycles of CAPOX chemotherapy (CT), were assessed for surgical feasibility for the primary and metastatic sites. Results: Sixty‐five patients could complete the planned SCRT and three to six cycles of CT. Response rate and disease control rate for the primary was 68% and 97%, respectively. Radiologically, CRM became free in 44 (72%) patients out of 61 initially involved. Fifty‐two (74%) were planned to receive treatment with a potentially curative intent and 18 (26%) with palliative intent. Of those treated with curative intent, 34 (65%) underwent primary tumor resection (PTR). Successful intervention for metastatic disease was done in 27 (52%) patients. At a median follow up of 43 months, the median overall survival (OS) for patients undergoing PTR was 36 months versus 12 months for those in which the tumor was still unresectable or had distant progression (P <.001). Of the operated patients, 56% were alive at the end of 3 years. The median pelvic recurrence free survival was 29 months. Symptom control in the form of pain and bleeding control was observed in 80%. Conclusion: The addition of SCRT to CT in mLARC can downstage the primary tumor to undergo surgery, thereby, achieving better loco‐regional control and survival. It achieves good palliation in patients unable to undergo surgery due to extensive primary or metastatic disease. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network.
- Author
-
Chopra, Supriya, Mangaj, Akshay, Sharma, Alisha, Tan, Li Tee, Sturdza, Alina, Jürgenliemk-Schulz, Ina, Han, Kathy, Huang, Fleur, Schmid, Maximilian P., Fokdal, Lars, Chargari, Cyrus, Diendorfer, Tamara, Tanderup, Kari, Potter, Richard, and Nout, Remi A
- Subjects
- *
CERVICAL cancer , *CANCER treatment , *ONCOLOGISTS , *RADIOTHERAPY , *CHEMORADIOTHERAPY , *RADIATION doses , *CERVIX uteri diseases - Abstract
• The survey results described in the manuscript captures the heterogeneity in the clinical practice of oligometastatic and oligorecurrent cervical cancer. • This survey will help to define the role of radiation therapy in oligometastatic and oligorecurrent cervical cancer. • This survey highlights the desire of radiation oncologists over the globe to practice stereotactic radiation therapy in oligometastatic disease and will help to plan future clinical trials. In the metastatic or recurrent cervical cancer, systemic chemotherapy constitutes the main treatment. Though there is an increasing use of high dose external radiation and brachytherapy in the metastatic setting, no consensus exists. A 17-item survey was designed with additional case-based questions to explore present management of oligo-metastatic and oligo-recurrent cervix cancer within EMBRACE research group participating sites. The questions were designed to elicit prevailing practices in the management of de-novo oligo-metastasis and oligo-recurrent setting after completing the primary treatment of cervix cancer. The survey was sent electronically with two rounds of email reminders to respond over a 2-week survey period. The online survey was designed such that it was mandatory to complete all questions. The responses were recorded and results were summarized as proportions and summary statistics were generated. Twenty-two centers responded to this survey. A majority (90%) of respondents reported a low incidence of de-novo oligo-metastatic cervical cancer in their practice (<5%), with a higher proportion of patients with oligo-recurrence after completing primary treatment (5–10%). All responding sites preferred to treat pelvic disease in the de-novo oligo-metastatic setting albeit with different fractionation regimens. While 68.2% of respondents recommended chemo-radiation and brachytherapy, 31.8% considered additional systemic therapy. Overall 77.3% centers recommended the use of stereotactic ablative radiation therapy to oligo-metastasis. For out-of-field nodal recurrences, 63.7% of respondents considered treating with curative intent, while 59% preferred treating in-field recurrence with palliative intent. A vast majority of the participating centers (90%) have stereotactic radiation therapy capacity and would consider a clinical trial addressing oligo-metastatic and oligo-recurrent cervical cancer. Although contemporary practice is variable, a substantial proportion of EMBRACE centers consider high dose radiation in de-novo metastatic and oligo-recurrence settings. However, there is clear need for a joint clinical protocol and prospective studies to address the role of high dose radiation within oligo-recurrent and oligo-metastatic scenarios. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Implementation of a visual feedback system for motion management during radiation therapy.
- Author
-
Swamidas, Jamema, Rose, John, Chopra, Supriya, Paul, Siji, Joshi, Kishore, Panda, Subhajit, Ph, Reena, Agarwal, Jai, Paul, Siji N, and Agarwal, Jai Prakash
- Subjects
LOCAL area networks ,RADIOTHERAPY ,LINEAR accelerators ,IMAGE-guided radiation therapy - Abstract
Purpose: To describe the details of an in-house video goggles feedback system assembled from several commercially available components. The objective of this paper is to share our experience with this system, provide details on the equipment needed, system assembly, patient set up and user settings on some components.Materials and Methods: The system consisted of goggles (FPView3DHD, ITV, USA), RJ45(Registered Jack) to Digital Visual Interface (DVI) converter (Tripplite), DVI to HDMI converters, Local Area Network(LAN) cable, HDMI and power extender cables. The video coaching system was implemented both in CT simulator (GE Discovery)) and in treatment delivery machine True Beam v2.1 Varian Medical Systems (VMS, Palo Alto), which was integrated with respiratory motion management (RPM V 1.7.5) system.Results: The video feedback system is in clinical use since Aug 2017, so far, we have treated 13 patients, with approximately 150 fractions. The performance of the device was found to be satisfactory. All the patients were coached for DIBH and the usage of the goggles, which includes wearing the goggles, display details of the monitor, and the threshold levels of the breathing wave cycle. The patients understand the instructions very well and hence regulate the breathing cycle, which improves the treatment accuracy and efficiency.Conclusion: Video feedback system for motion management, for patients undergoing radiotherapy was implemented successfully both in CT simulator and in linear accelerator. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
12. Cancer Stem Cells, CD44, and Outcomes Following Chemoradiation in Locally Advanced Cervical Cancer: Results From a Prospective Study.
- Author
-
Chopra, Supriya, Deodhar, Kedar, Pai, Venkatesh, Pant, Sidharth, Rathod, Nidul, Goda, Jayant S., Sudhalkar, Niyati, Pandey, Puloma, Waghmare, Sanjeev, Engineer, Reena, Mahantshetty, Umesh, Ghosh, Jaya, Gupta, Sudeep, and Shrivastava, Shyam
- Subjects
- *
CANCER stem cells , *CERVICAL cancer , *CERVICAL cancer treatment , *IMMUNOHISTOCHEMISTRY , *RADIOTHERAPY , *RADIOISOTOPE brachytherapy - Abstract
Purpose: Although cancer stem cells (CSCs) have been reported across solid tumors, there is a dearth of data regarding CSC and its impact on outcomes of cervical cancer.Methods and Materials: From October 2013 to December 2015, patients with squamous cancer of the cervix (stage IB2-IVA) were included. Pretreatment and posttreatment biopsy was obtained and immunohistochemistry was performed for SOX-2, OCT-4, Nanog, CD44, and Podoplanin. All patients received concurrent radiation and brachytherapy to an equivalent dose of 80 to 84 Gy to point A with concurrent weekly cisplatin. Correlation of CSC expression was performed with known prognostic factors. The effect of stem cell expression on disease outcomes was tested within multivariate analysis.Results: One hundred fifty patients were included. The median dose to point A was 83 Gy (46-89 Gy) and a median of 4 cycles (range, 0-6 cycles) of chemotherapy was administered. At baseline, moderate to strong immunohistochemical expression of SOX-2, OCT-4, Nanog, CD44, and Podoplanin was observed in 12.8%, 4.8%, 24.4%, 15.5%, and 1.3% of patients, respectively. At median follow-up of 30 months (range, 3-51 months), locoregional and distant relapse was observed in 12.2% and 23.1% of patients, of whom 4.7% had both local and distant relapse. The 3-year disease-free survival rate was 87%. On multivariate analysis, moderate to high CSC expression and CD44 low status (hazard ratio [HR] = 8.8; 95% confidence interval [CI], 1.0-77.2; P < .04) independently predicted for locoregional relapse-free survival. International Federation of Gynecology and Obstetrics stage (HR = 2.6; 95% CI, 1.3-5.4; P = .004) and presence of residual tumor after external radiation (HR = 3.5; 95% CI, 1.8-6.5; P = .0001) predicted for a detriment in disease-free survival.Conclusions: The presence of stem cell proteins and loss of CD44 independently predicts for reduced locoregional control in locally advanced cervical cancer. Further investigation into the interaction of stem cell and CD44 biology is warranted. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
13. A comparative analysis of quality of life after postoperative intensity-modulated radiotherapy or three-dimensional conformal radiotherapy for cervical cancer.
- Author
-
Mohanty, Sarthak Kumar, Chopra, Supriya, Mudaliar, Anisha, Kannan, Sadhana, Mahantshetty, Umesh, Engineer, Reena, Ghosh, Jaya, Bajpai, Jyoti, Gupta, Sudeep, and Shrivastava, Shyamkishore
- Subjects
- *
INTENSITY modulated radiotherapy , *CERVICAL cancer , *APPETITE loss , *QUALITY of life , *CANCER radiotherapy , *MORNING sickness , *CLIMACTERIC , *RESEARCH , *PAIN , *RESEARCH methodology , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *POSTOPERATIVE period , *RADIOTHERAPY , *INSOMNIA , *EMOTIONS , *LONGITUDINAL method ,CERVIX uteri tumors - Abstract
Aims: The aim of this study is to compare the quality of life (QOL) between adjuvant three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT) for cervical cancer.Materials and Methods: QOL assessment was done at the baseline and then longitudinally after completing (chemo) radiation. All patients completed EORTC QLQ-C30 and EORTC QLQ Cx-24 modules. Independent-sample t-test was used to compare the mean scores between the two groups. Analysis of variance was used to compare differences in QOL measures over the six time points (baseline, post-RT, 3, 6, 9, and 12 months after treatment) and between treatment groups (3DCRT vs. IMRT). Linear mixed model was also performed to account for attrition.Results: Overall, 64 patients (image-guided IMRT, n = 40 and 3DCRT, n = 24) completed QOL assessment. The median age and follow-up period were 48 years and 15.5 months, respectively. General QOL domains such as emotional (at 12 months, P = 0.04) and social (at 3 months, P = 0.02 and 12 months, P = 0.03) were better with IMRT. Pain (12 months, P = 0.03); fatigue (12 months, P = 0.05); nausea and vomiting (12 months, P = 0.03); insomnia (post-RT, P = 0.05 and 12 months, P = 0.03); appetite loss (post-RT and 12 months, P = 0.04); and diarrhea (6 months, P = 0.02 and 12 months, P = 0.003) scores were significantly better with IMRT. On linear mixed model analysis, there was a significant interaction between treatment cohort and assessment intervals for physical, emotional, and social functioning, appetite loss, diarrhea, lymphedema, and menopausal symptom scores were significantly better with IMRT.Conclusions: Treatment technique (IMRT vs. 3DCRT) impacts early QOL in undergoing adjuvant radiation for cervical cancer. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
14. Recent Key Studies in Cancers of the Uterine Corpus and Cervix: New Updates in Immunotherapy, the Microbiome, Bone Density, Quantifying Lymphovascular Invasion, and Hypofractionated Pelvic Radiation Therapy.
- Author
-
Harkenrider, Matthew, Fields, Emma, Chopra, Supriya, Damast, Shari, Kidd, Elizabeth A., and Chino, Junzo
- Subjects
- *
CERVICAL cancer , *BONE density , *RADIOTHERAPY , *IMMUNOTHERAPY , *PELVIC bones , *MULLERIAN ducts - Published
- 2023
- Full Text
- View/download PDF
15. Assessment of three-dimensional set-up errors in conventional head and neck radiotherapy using electronic portal imaging device.
- Author
-
Gupta, Tejpal, Chopra, Supriya, Kadam, Avinash, Agarwal, Jai Prakash, Devi, P. Reena, Ghosh-Laskar, Sarbani, and Dinshaw, Ketayun Ardeshir
- Subjects
- *
RADIOTHERAPY , *MEDICAL radiology , *HOSPITAL radiological services , *MEDICAL electronics , *PHOTOTHERAPY , *DIAGNOSTIC imaging - Abstract
Background: Set-up errors are an inherent part of radiation treatment process. Coverage of target volume is a direct function of set-up margins, which should be optimized to prevent inadvertent irradiation of adjacent normal tissues. The aim of this study was to evaluate three-dimensional (3D) set-up errors and propose optimum margins for target volume coverage in head and neck radiotherapy. Methods: The dataset consisted of 93 pairs of orthogonal simulator and corresponding portal images on which 558 point positions were measured to calculate translational displacement in 25 patients undergoing conventional head and neck radiotherapy with antero-lateral wedge pair technique. Mean displacements, population systematic (Σ) and random (σ) errors and 3D vector of displacement was calculated. Set-up margins were calculated using published margin recipes. Results: The mean displacement in antero-posterior (AP), medio-lateral (ML) and supero-inferior (SI) direction was -0.25 mm (-6.50 to +7.70 mm), -0.48 mm (-5.50 to +7.80 mm) and +0.45 mm (-7.30 to +7.40 mm) respectively. Ninety three percent of the displacements were within 5 mm in all three cardinal directions. Population systematic (Σ) and random errors (σ) were 0.96, 0.98 and 1.20 mm and 1.94, 1.97 and 2.48 mm in AP, ML and SI direction respectively. The mean 3D vector of displacement was 3.84 cm. Using van Herk's formula, the clinical target volume to planning target volume margins were 3.76, 3.83 and 4.74 mm in AP, ML and SI direction respectively. Conclusion: The present study report compares well with published set-up error data relevant to head and neck radiotherapy practice. The set-up margins were <5 mm in all directions. Caution is warranted against adopting generic margin recipes as different margin generating recipes lead to a different probability of target volume coverage. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
16. Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin.
- Author
-
Lewis, Shirley, Chopra, Supriya, Naga, Pushpa, Pant, Siddharth, Dandpani, Epili, Bharadwaj, Naveen, Mahantshetty, Umesh, Engineer, Reena, Swamidas, Jamema, Ghosh, Jaya, Gupta, Sudeep, and Shrivastava, Shyam
- Subjects
- *
HEMATOLOGIC malignancies , *RADIOTHERAPY , *CISPLATIN , *GASTROINTESTINAL system abnormalities , *CANCER chemotherapy , *CERVICAL cancer - Abstract
To report acute hematological toxicity (HT) in patients receiving post-operative bowel sparing intensity-modulated radiotherapy (IMRT) and cisplatin and its dosimetric predictors. Clinical database of Phase III trial (NCT01279135), that randomized patients to post-operative conformal or intensity modulated radiation therapy, was searched to select patient strata that received bowel sparing IMRT (50 Gy/25#/5 wks) and concurrent cisplatin (40 mg m–2). Pelvic bone marrow (BM) was retrospectively delineated in two sets: whole bone (WB), and freehand (FH) inner cavity of bone. Dose volume histograms (DVH) of BM were obtained. Receiver operating characteristic (ROC) curve identified DVH thresholds that predicted for Grade≥ II HT with highest specificity. Univariate and multivariate analysis was performed. Overall 75 patients received concurrent cisplatin. Grades I–V HT was observed in 38.7%, 42.7%, 14.7%, 0%, and 0% patients, respectively. Grade ≥ II leukopenia, neutropenia, anemia, and thrombocytopenia were observed in 26%, 40%, 26.5%, and 1.4% respectively. None of the HT resulted in treatment break. On univariate analysis, whole pelvis+ lumbar FH V30 >55% & V40>35%, whole pelvis WB and FH V40 > 35%, and lower pelvis WB and FH V40 >20% correlated for Grade ≥ II leucopenia and neutropenia. None of the BM dose volume constraints predicted for overall HT or neutropenia on multivariate analysis. The IMRT arm of NCT01279135 (PARCER study) that employed strict bowel constraints had unintentional but desirable BM sparing. None of the BM subvolume DVH parameters could be validated on multivariate analysis. The prospective study reports feasibility of bone marrow sparing with bowel sparing post-operative pelvic IMRT and concurrent chemotherapy for cervical cancer. The present study reports low incidence of hematological and gastrointestinal toxicity during post-operative chemoradiation with IMRT. As both whole bone and freehand pelvis BM contours predicted for HT, hence an easier method of whole bone contouring should continue to be used till further validation of more specific BM subvolumes becomes available. The study results highlight the need for further research into dose volume constraints during post-operative IMRT. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
17. Pathological Predictors for Site of Local Recurrence After Radiotherapy for Prostate Cancer
- Author
-
Chopra, Supriya, Toi, Ants, Taback, Nathan, Evans, Andrew, Haider, Masoom A., Milosevic, Michael, Bristow, Robert G., Chung, Peter, Bayley, Andrew, Morton, Gerard, Vesprini, Danny, Warde, Padraig, Catton, Charles, and Ménard, Cynthia
- Subjects
- *
PROSTATE cancer , *CANCER radiotherapy , *CANCER relapse , *BIOPSY , *MEDICAL statistics , *CLINICAL trials - Abstract
Purpose: Rational design of targeted radiotherapy (RT) in prostate cancer (Pca) hinges on a better understanding of spatial patterns of recurrence. We sought to identify pathological factors predictive for site of local recurrence (LR) after external beam RT. Methods and Materials: Prospective databases were reviewed to identify men with LR after RT from 1997 through 2009. Patients with biochemical failure and biopsy-confirmed Pca more than 2 years after RT were evaluated. Prediction for site of recurrence based on the following pretreatment factors was determined on independent and cluster-sextant basis: presence of malignancy, dominant vs. nondominant percentage core length (PCL) involvement, PCL ≥ or <40%, and Gleason score. Sites of dominant PCL were defined as sextants with peak PCL involvement minus 10%, and >5% for each patient. Results: Forty-one patients with low-intermediate risk Pca constituted the study cohort. Median time to biopsy after RT was 51 months (range, 24–145). Of 246 sextants, 74 were involved with tumor at baseline. When sextants are treated as independent observations the presence of malignancy (77% vs. 22%, p = 0.0001), dominant PCL (90% vs. 46%, p = 0.0001), and PCL ≥40% (89% vs. 68 %, p = 0.04) were found to be significant predictors for LR, although PCL ≥40% did not retain statistical significance if sextants were considered correlated. The vast majority of patients (95%) recurred at the original site of dominant PCL or PCL ≥40%, and 44% also recurred in regions of nondominant PCL <40% (n = 8) and/or benign sampling (n = 14) at baseline. Conclusions: LR after RT predominantly occurs in regions bearing higher histological tumor burden but are not isolated to these sites. Our data highlights the value of spatially resolved baseline pathological sampling and may assist in the design of clinical trials tailoring RT dose prescriptions to subregions of the prostate gland. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
18. Radiation therapy for gynecologic malignancies during the COVID-19 pandemic: International expert consensus recommendations.
- Author
-
Elledge, Christen R., Beriwal, Sushil, Chargari, Cyrus, Chopra, Supriya, Erickson, Beth A., Gaffney, David K., Jhingran, Anuja, Klopp, Ann H., Small, William, Yashar, Catheryn M., and Viswanathan, Akila N.
- Subjects
- *
COVID-19 pandemic , *RADIOTHERAPY , *VAGINAL cancer , *VULVAR cancer , *UTERINE cancer - Abstract
To develop expert consensus recommendations regarding radiation therapy for gynecologic malignancies during the COVID-19 pandemic. An international committee of ten experts in gynecologic radiation oncology convened to provide consensus recommendations for patients with gynecologic malignancies referred for radiation therapy. Treatment priority groups were established. A review of the relevant literature was performed and different clinical scenarios were categorized into three priority groups. For each stage and clinical scenario in cervical, endometrial, vulvar, vaginal and ovarian cancer, specific recommendations regarding dose, technique, and timing were provided by the panel. Expert review and discussion generated consensus recommendations to guide radiation oncologists treating gynecologic malignancies during the COVID-19 pandemic. Priority scales for cervical, endometrial, vulvar, vaginal, and ovarian cancers are presented. Both radical and palliative treatments are discussed. Management of COVID-19 positive patients is considered. Hypofractionated radiation therapy should be used when feasible and recommendations regarding radiation dose, timing, and technique have been provided for external beam and brachytherapy treatments. Concurrent chemotherapy may be limited in some countries, and consideration of radiation alone is recommended. The expert consensus recommendations provide guidance for delivering radiation therapy during the COVID-19 pandemic. Specific recommendations have been provided for common clinical scenarios encountered in gynecologic radiation oncology with a focus on strategies to reduce patient and staff exposure to COVID-19. • An international panel of gynecologic radiation oncologists offer recommendations for RT during the COVID-19 pandemic. • Recommendations for cervical cancer, uterine cancer, vulvar cancer, vaginal cancer and ovarian cancer have been provided. • Recommendations for RT timing, fractionation, and dose have been provided for external beam radiation and brachytherapy. • The panel emphasizes strategies to reduce risk of transmission of the novel SARS-CoV-2 to patients and healthcare workers. • These recommendations may be used any time an event occurs which limits healthcare resources, including natural disasters. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. Utilization of a Web-Based Conferencing Platform to Improve Global Radiation Oncology Education and Quality-Proof of Principle Through Implementation in India.
- Author
-
Robin, Tyler P., Grover, Surbhi, Reddy Palkonda, Vijay Anand, Fisher, Christine M., Gehl, Brigitta, Bhattacharya, Kausik, Mallick, Indranil, Bhattasali, Onita, Viswanathan, Akila N., Sastri (Chopra), Supriya, Mahantshetty, Umesh, and Hardenbergh, Patricia H.
- Subjects
- *
RADIOTHERAPY , *ONCOLOGISTS , *RADIOISOTOPE brachytherapy , *ONCOLOGY , *MAGNETIC resonance imaging - Abstract
Purpose: Chartrounds (www.chartrounds.com) was established in the United States in 2010 as a web-based platform for radiation oncologists to review cases with leading disease-site experts. However, the need for access to experts for peer review and education is not unique to the United States, and the Chartrounds platform was therefore adapted for improved global reach. Chartrounds was first expanded to India, and herein we report our initial experience with this initiative.Methods and Materials: The US Chartrounds platform was adapted to create Chartrounds India (ind.chartrounds.com). Through collaboration with the Association of Radiation Oncologists of India, India-based specialists were recruited, and the association's membership list was used to announce sessions to potential participants.Results: Between June 2017 and January 2018, 27 Chartrounds India sessions were completed, led by 21 different specialists (representing 10 centers in India) and covering 11 different disease sites/topics. A total of 240 members from 126 centers (private: 56%; teaching: 36%; public: 8%) across 24 states/territories participated in ≥1 session. Of the 240 members who participated in ≥1 session, 159 (66%) participated in ≥2 sessions and 60 (25%) participated in ≥5 sessions. The average number of participants per session was 34 (range, 13-72). On average, 80% of respondents rated the sessions as high or very high quality; 87% and 95% agreed or strongly agreed that the time was used effectively and that the sessions were relevant to daily practice, respectively. Seventy-six percent agreed or strongly agreed that the sessions will result in a change in their practice. The average feedback survey response rate was 32% (range, 17%-49%).Conclusions: Chartrounds has proven to be an effective resource for US-based radiation oncologists, and our initial experience with Chartrounds India suggests that an online platform for radiation oncology case review and education can be successfully implemented globally with use of local disease site experts. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
20. A Prospective Comparison of Computed Tomography with Transrectal Ultrasonography Assistance and Magnetic Resonance Imaging-Based Target-Volume Definition During Image Guided Adaptive Brachytherapy for Cervical Cancers.
- Author
-
Mahantshetty, Umesh, Naga CH, Pushpa, Khadanga, Chira Ranjan, Gudi, Shivakumar, Chopra, Supriya, Gurram, Lavanya, Jamema, Swamidas, Ghadi, Yogesh, and Shrivastava, Shyamkishore
- Subjects
- *
TOMOGRAPHY , *COMPUTED tomography , *MEDICAL radiography , *GEOMETRIC tomography , *ULTRASONIC imaging , *COMPARATIVE studies , *MAGNETIC resonance imaging , *RESEARCH methodology , *MEDICAL cooperation , *RADIOISOTOPE brachytherapy , *RADIOTHERAPY , *RECTUM , *RESEARCH , *EVALUATION research ,CERVIX uteri tumors - Abstract
Purpose: Although magnetic resonance imaging (MRI) represents the gold standard for image guided adaptive brachytherapy (IGABT) for cervical cancer, the majority of brachytherapy (BT) continues to be guided by computed tomography (CT). However, CT seems to overestimate the target-volume definition, and the potential of transrectal ultrasonography (TRUS) needs further evaluation. This prospective, comparative study aimed to evaluate CT-based target contouring with the incorporation of TRUS during BT.Methods and Materials: Patients with locally advanced cervical cancer undergoing magnetic resonance IGABT between January 2013 and March 2014 were included. During the BT procedure, TRUS imaging with central tandem in situ was acquired at 3 representative levels. Reference points/dimensions (D1-D4) of the hypoechoic region on TRUS images with respect to the central tandem were recorded. CT and magnetic resonance BT planning imaging was performed after BT application. The high-risk clinical target volume (HR-CTV) was contoured on CT scans with incorporation of clinical and TRUS imaging findings and was compared with the gold standard MRI-based target approach.Results: The image sets of 25 patients (International Federation of Gynecology and Obstetrics clinical stage IIB [11; 44%] and IIIB [14; 56%]) were evaluable. The mean (±standard deviation) volumes of HR-CTV on CT and MRI imaging were 39.1 (±20) cm³ and 39 (±19) cm³, respectively (r = 0.92; P < .001). A significant correlation was found between the HR-CTV dimensions (width and thickness) of CT and MRI scans at various levels (r = 0.70-0.80; P < .001). In addition, the absolute differences in target dimensions between CT and MRI were <0.5 cm. A strong correlation was seen between CT and MRI for patients with medial and lateral parametrial invasion (P < .05) compared with no parametrial disease at BT. Furthermore, the mean differences in HR-CTV width between CT and MRI contours at various levels, irrespective of parametrial involvement, was only 0.1 to 0.4 cm.Conclusions: This study suggests that a CT-based target and organ-at-risk delineation using MRI at diagnosis and real-time TRUS information during BT seems comparable with the gold standard MRI-based approach in IGABT for cervical cancer. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.